使用乙烯-乙烯醇共聚物(Onyx®)经动脉栓塞治疗外周高流量动静脉畸形:单中心10年经验
该单中心回顾性分析纳入16例高流量外周动静脉畸形患者,共行38次经动脉Onyx®栓塞操作,11例获得技术成功,30天随访15例症状改善,但近1年后7例症状复发并出现影像学复发征象,无临床相关并发症。
要点
- Onyx®经动脉栓塞高流量外周动静脉畸形技术成功11/16例,30天随访15例症状改善。
- 近1年后7例出现症状复发及影像学动静脉畸形复发征象。
- 无临床相关并发症,但需警惕新供血动脉募集,患者应知晓可能需要多次治疗。
核心结论
- 在本系列中,与既往有限发表数据一致,Onyx®经动脉途径栓塞高流量外周动静脉畸形似乎安全且技术上有效;临床影像随访是必须的,因为新供血动脉募集是可预期的;应告知患者确实存在多次治疗的可能性。
研究设计与样本
- 单中心10年经验的回顾性分析,纳入择期行经动脉Onyx®栓塞的高流量动静脉畸形患者16例,共38次栓塞操作;收集介入前临床影像评估、操作数据及术后临床影像评估,随访在末次治疗 session 后30天进行,成功者每年随访。
诊断标准与关键数值
- 技术成功定义为获得技术成功,16例中11例获得技术成功。
- 30天随访时15例症状改善,包括栓塞不完全者。
- 治疗后近1年7例出现症状复发并伴动静脉畸形复发的影像学征象。
- 5例需要额外的栓塞剂。
临床应用与阅片要点
- 作者认为Onyx®经动脉栓塞高流量外周动静脉畸形似乎安全且技术上有效。
- 作者指出临床影像随访是必须的,因为新供血动脉募集是可预期的。
- 作者建议应告知患者确实存在多次治疗的可能性。
- 本系列中无临床相关并发症发生。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: High-flow arteriovenous malformations (AVMs) are complex vascular lesions for which transcatheter embolization is considered as first-choice treatment nowadays. Multiple embolizing agents have been described, and among them, Onyx® seems to be promising; this is a liquid embolic agent, originally applied in neurointerventional radiology and recently adopted also in peripheral embolizations. The aim of this study is to report on a 10-year experience of transarterial embolization of peripheral high-flow AVM with Onyx® in terms of technical and clinical outcomes.
MATERIALS AND METHODS: Retrospective analysis was conducted on patients affected by high-flow AVM and treated electively by transarterial embolization with Onyx®. Data collection included: preinterventional clinical radiological evaluations, procedural data and post-procedural clinical radiological assessment. Technical and clinical success was evaluated; follow-up was conducted 30 days after the last treatment session and yearly in case of success.
RESULTS: Sixteen patients have been included, totally 38 embolizing procedures. Additional embolizing agents were required in 5 patients. Technical success was obtained in 11 patients; at 30-day follow-up, 15 patients showed improvements in symptoms, even those with incomplete embolization; however, after almost 1 year from treatment accomplishment, 7 patients showed relapse of symptoms and presented radiological signs of AVM recurrence. No clinically relevant complications occurred.
CONCLUSIONS: In this series, in accordance with previous but limited published data, Onyx® appeared safe and technically effective to embolize high-flow peripheral AVM with transarterial approach. Clinical radiological follow-up is mandatory because new feeder recruitment has to be expected; patients should be informed of the concrete possibility of multiple treatment sessions.
引用
- Giurazza F, Corvino F, Cangiano G, et al. Transarterial embolization of peripheral high-flow arteriovenous malformation with ethylene vinyl alcohol copolymer (Onyx®): single-center 10-year experience. Radiol Med. 2018. PMID: 30368719. doi:10.1007/s11547-018-0948-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。